As per the official reports from Teva Pharmaceutical Industries, the Phase II trial of its Talampanel drug that is the potential treatment for Amyotrophic Lateral Sclerosis has failed.

Amyotrophic Lateral Sclerosis is commonly known as Lou Gehrig's disease as figures reveal that over 10,000 people in the United States and Europe are diagnosed each year with this dreadful disease.

Further it is estimated that around 50,000 people worldwide suffer from the disease that can prove fatal at any given time.

Experts explain that Lou Gehrig's disease is a degenerative motor neuron disease that can lead to paralysis and, subsequently, to death, within the time frame from three to five years from its onset.

They further add that respiratory failure is the most common cause of death. Muscle weakness in limbs, muscle twitching (fasciculation) and cramping, speech impediments, and difficulty in swallowing and respiratory impairment are the progressive symptom of the lethal disease.

As per the reports, Teva Pharmaceutical had designed the trail to evaluate Talampanel's efficacy, safety and tolerability in the reduction of the disease-related functional deterioration in ALS patients.

However, the as per the results, while Talampanel was considered safe, it did not meet its primary goals that were set by the company.

Manor, Teva's Vice President for Global Branded Products said, "This outcome has no impact on our 2015 innovative goal. Broadening our innovative pipeline - through internal R&D, licensing and other business development activities - is part of our long-term strategy".